VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications.

VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications.
复制标题

DOI:
10.1007/s11912-022-01224-0
复制
发表时间:
2022-04
影响因子:
4.7
通讯作者:
--
中科院分区:
医学2区
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

虽然血管内皮生长因子受体抑制剂(VEGFRis)显著提高了癌症患者的生存率,但这些药物在大多数患者中导致高血压。这种副作用通常是剂量限制,并增加癌症幸存者的心血管死亡率。本文综述了影响vegfr诱导高血压管理的分子机制和临床发现方面的最新进展。最近的研究确定了内皮功能障碍与vegfr诱导的高血压之间的新联系,包括一氧化氮、氧化应激、内皮素信号传导和前列腺素之间的平衡,以及微颗粒、血管平滑肌细胞、血管僵硬和微血管稀薄的潜在作用。本文综述了基因多态性可能识别vegfr -诱导高血压患者风险的数据,以及越来越多将vegfr -诱导高血压与抗肿瘤疗效联系起来的文献。这些最新进展对未来的心脏肿瘤学临床和vegfr诱导高血压的管理具有重要意义。
While vascular endothelial growth factor receptor inhibitors (VEGFRis) have dramatically improved cancer survival, these drugs cause hypertension in a majority of patients. This side effect is often dose limiting and increases cardiovascular mortality in cancer survivors. This review summarizes recent advances in our understanding of the molecular mechanisms and clinical findings that impact management of VEGFRi-induced hypertension. Recent studies define new connections between endothelial dysfunction and VEGFRi-induced hypertension, including the balance between nitric oxide, oxidative stress, endothelin signaling, and prostaglandins and the potential role of microparticles, vascular smooth muscle cells, vascular stiffness, and microvessel rarefaction. Data implicating genetic polymorphisms that might identify patients at risk for VEGFRi-induced hypertension and the growing body of literature associating VEGFRi-induced hypertension with antitumor efficacy are reviewed. These recent advances have implications for the future of cardio-oncology clinics and the management of VEGFRi-induced hypertension.
DOI: 10.1186/s40959-020-00064-w
发表时间: 2020-07-13
期刊: CARDIO-ONCOLOGY
影响因子: 3.3
作者:
Dabire, Hubert;Drame, Fatou;Ghaleh, Bijan
通讯作者: Ghaleh, Bijan
DOI: 10.1161/circheartfailure.117.004408
发表时间: 2018-03
期刊: Circulation. Heart failure
影响因子: --
作者:
Catino AB;Hubbard RA;Chirinos JA;Townsend R;Keefe S;Haas NB;Puzanov I;Fang JC;Agarwal N;Hyman D;Smith AM;Gordon M;Plappert T;Englefield V;Narayan V;Ewer S;ElAmm C;Lenihan D;Ky B
通讯作者: Ky B
DOI: 10.1056/nejmoa0707330
发表时间: 2008-03-13
影响因子: 158.5
作者:
Eremina, Vera;Jefferson, J. Ashley;Quaggin, Susan E.
通讯作者: Quaggin, Susan E.
DOI: 10.1634/theoncologist.2012-0339
发表时间: 2013-03-01
期刊: ONCOLOGIST
影响因子: 5.8
作者:
Hurwitz, Herbert I.;Douglas, Pamela S.;Rosen, Oliver
通讯作者: Rosen, Oliver
DOI: 10.2165/00003495-199700531-00003
发表时间: 1997-01-01
期刊: DRUGS
影响因子: 11.5
作者:
Haller, H
通讯作者: Haller, H